MedTrace Logo

Neoadjuvant Nivolumab for Oral Cancer Combined With FDG and Anti-PD-L1 PET/CT Imaging for Response Prediction

NCT03843515 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2021-10-08

No results posted yet for this study

Summary

Safety and tolerability of neoadjuvant nivolumab for locally advanced resectable oral cancer, combined with \[18F\]BMS-986192 / \[18F\]-FDG PET imaging and immunomonitoring for response prediction

Conditions

  • Oral Cavity Squamous Cell Carcinoma

Interventions

DRUG

Nivolumab

Neoadjuvant nivolumab flat dose 400mg

Sponsors & Collaborators

Principal Investigators

  • C. W. Menke, Phd, MD · Amsterdam UMC, location VUmc

  • C. R. Leemans, Phd, MD · Amsterdam UMC, location VUmc

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-11
Primary Completion
2021-11-30
Completion
2022-08-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03843515 on ClinicalTrials.gov